Results 1 to 10 of about 2,667,430 (358)
The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study [PDF]
BMC Urology, 2021 Background Combination drug therapy for lower urinary tract symptoms (LUTS) is beneficial to selected patients and recommended by guidelines. Patterns of real-world LUTS drug use, especially combination drug therapy, have not been studied extensively ...
Mahmood Ali +6 more
doaj +2 more sources
Nanoparticles for Combination Drug Therapy [PDF]
ACS Nano, 2013 Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted ...
Liang Ma, Andrew M. Smith, Manish Kohli
openaire +4 more sources
Combination Drug Therapy for the Management of Alzheimer’s Disease
International Journal of Molecular Sciences, 2020 Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs.
Rasha A. Mansouri +10 more
openaire +9 more sources
Drug combination therapy for emerging viral diseases
Drug Discovery Today, 2021 Effective therapeutics to combat emerging viral infections are an unmet need. Historically, treatments for chronic viral infections with single drugs have not been successful, as exemplified by human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections.
Zeenat A. Shyr +3 more
openaire +3 more sources
Nanocarrier-based drug combination therapy for glioblastoma
Theranostics, 2020 The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem cells, drug efflux pumps and DNA damage repair mechanisms. Drug combination therapies have shown increasing benefits against those challenges. With the help of nanocarriers,
Zhao, M.N. +4 more
openaire +7 more sources
Combination Drug Therapy in Refractory Epilepsy
Pediatric Neurology Briefs, 2012 Researchers from University of Washington, Seattle, WA analyzed the treatment records from 148 developmentally disabled adults with refractory epilepsy cared for in 2 state-run institutions.
J Gordon Millichap
doaj +4 more sources
Drug combination therapy increases successful drug repositioning [PDF]
Drug Discovery Today, 2016 Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years.
Wei Sun, Philip E. Sanderson, Wei Zheng
openaire +4 more sources
Artificial intelligence in drug combination therapy
Briefings in Bioinformatics, 2018 AbstractCurrently, the development of medicines for complex diseases requires the development of combination drug therapies. It is necessary because in many cases, one drug cannot target all necessary points of intervention. For example, in cancer therapy, a physician often meets a patient having a genomic profile including more than five molecular ...
I. Tsigelny
openaire +3 more sources
Quantifying the pharmacology of antimalarial drug combination therapy [PDF]
Scientific Reports, 2016 AbstractMost current antimalarial drugs are combinations of an artemisinin plus a ‘partner’ drug from another class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs in treating human malaria infections.
Katherine Kay +2 more
openaire +6 more sources
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n ...
Soon-Jib Yoo +8 more
doaj +1 more source